NASDAQ
3.70USD
-0.16 (-4.15%)
We have scored 17 news catalysts on TriSalus Life Sciences, Inc. (TLSI) over the past 12 months. The biggest single-day move next to one of them came May 15, 2026, when TLSI closed +6.3%: “Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details”. Coverage across the window leans negative (average ticker sentiment −0.52). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
227.8M
P/E
—
EPS
—
Beta
0.47
52W range
2.2-7.95
Day range
3.66–3.87
Open
3.83
Prev close
3.86
Volume
108.6K
Avg volume
289.6K
Dividend
0.00
IPO
2021-02-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about TriSalus Life Sciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TLSI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
